Cardiovascular Risk with Non-steroidal Anti-inflammatory Drugs: Clinical Implications

Drug Safety

Volumn 37, Issue 11, 2014, Pages 897-902

  Bello, Alfonso E ^a   Holt, Robert J ^b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; DICLOFENAC; ESOMEPRAZOLE; ETORICOXIB; FAMOTIDINE PLUS IBUPROFEN; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PLACEBO; ROFECOXIB; VALDECOXIB;

ADVISORY COMMITTEE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY BYPASS GRAFT; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG LABELING; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EDITORIAL; EQUIPOISE; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; LATENT PERIOD; LONG TERM CARE; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT COURSE THERAPY; CHEMICALLY INDUCED; RISK FACTOR; THROMBOSIS; UNITED STATES;

ADVISORY COMMITTEES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; DRUG LABELING; HUMANS; RISK FACTORS; THROMBOSIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84911407940     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0207-2     Document Type: Editorial

References (19)

1. US Food and Drug Administration. FDA briefing document on nonsteroidal anti-inflammatory drugs and cardiovascular thrombotic risk. Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management, Advisory Committee, February 10–11, 2014. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM383180.pdf. Accessed February 14, 2014.
2. Saag K, van der Heijde D, Fisher C, et al. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs. Arch Fam Med. 2000;9:1124–34.
3. Day R, Morrison B, Luza A, et al. A randomized trial of the efficacy and tolerability of the coxib rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med. 2000;160:1781–7.
4. Bensen WG, Fiechtner JJ, McMillen JI, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc. 1999;74(11):1095–105.
5. Celebrex® prescribing information. Pfizer, Inc; 2011.
6. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis the CLASS study: a randomized controlled trial. JAMA. 2000;284:1247–55.
7. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520–8.
8. Curfman GD, Morrissey S, Drazen JM. Expression of concern: Bombardier et al., “Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis”, N Engl J Med 2000;343:1520–1528. N Engl J Med. 2005;353:2813–4.
9. Curfman GD, Morrissey S, Drazen JM. Expression of concern reaffirmed. N Engl J Med. 2006;354:1193.
10. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092–102.
11. Baron JA, Sandler RS, Bresalier RS, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet. 2008;372(9651):1756–64.
12. Becker MC, Wang TH, Wisniewski L, et al. Rationale, design, and governance of prospective randomized evaluation of celecoxib integrated safety versus ibuprofen or naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J. 2009;157:606–12.
13. Schjerning Olsen A, Fosbøl EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011;123:2226–35.
14. Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–79. doi:10.1016/S0140-6736(13)60900-9 (Epub 2013 May 30).
15. European Medicines Agency, Press Release 06/28/2013, New safety advice for diclofenac—CMDh endorses PRAC recommendation. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001830.jsp&mid=WC0b01ac058004d5c1. Accessed 21 April 2014.
16. Altman DG, Bland JM. Statistics notes. Interaction revisited: the difference between two estimates. BMJ. 2003;326:219.
17. Olsen A, Fosbøl EL, Gislason GH. The impact of NSAID treatment on cardiovascular risk—insight from Danish observational data. Basic Clin Pharmacol Toxicol. 2014. doi:10.1111/bcpt.12244.
18. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728–38.
19. PL detail-document, managing NSAID risks. Pharmacist’s Letter/Prescriber’s Letter, July 2013.